Efficacy of Pharmacological Treatments for Dravet Syndrome: Systematic Review and Network Meta-Analysis

Dravet syndrome (DS), described as severe myoclonic epilepsy in infancy in 1978 by Dravet, is a rare genetic severe developmental and epileptic encephalopathy with a reported incidence of 1/16000 to 1/40000 [1,2,3]. DS is mainly caused by de novo mutations in the SCN1A gene (approximately 80%); however, several other genes have also been reported to cause DS or DS-like phenotypes [4].

0